Early assessment of clonal trajectories in CD34⁺ cells. (A) MRD level after allo-HSCT in a patient with temporary response to AZA treatment. For NGS-based MRD assessment, 2 available molecular marker (FLT3 c.2503G>T and TET1 c.5717insAATAG) were used. (B) Results of the NGS panel analysis in sorted CD34⁺ cells of MRD-positive samples obtained 131 and 455 days after allo-HSCT. (C) Clonal trajectories depicted from molecular profiles at AML diagnosis and CD34⁺ cells in complete hematological remission. (D) Detection of molecular lesions and corresponding variant allele frequencies (%) at AML diagnosis (gDNA from unsorted whole blood) and in CD34⁺ PB cells, sampled at the time of molecular relapse (after allo-HSCT) and hematological relapse (after AZA treatment) in 2 patients.